Middle East And Turkey Immune Thrombocytopenic Purpura (ITP) Treatment Drugs Market Value Accrue with Highest Revenue US$ 185 Million during 2020 to 2027, Owing to Increasing R&D in the Treatment of Immune Thrombocytopenic Purpura

Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Request FREE Sample

According to Middle East and Turkey Immune Thrombocytopenic Purpura (ITP) Treatment Drugs Market Report, by Drug Type (Steroid, Immunoglobulins, Thrombopoietin Receptor Agonist and Others, by Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Online Pharmacies), and by Country (Turkey, Israel, Egypt, Saudi Arabia, UAE, and Rest of Middle East), published by Coherent Market Insights, the Middle East and Turkey immune thrombocytopenic purpura (ITP) treatment drugs market was valued at US$  82.23 million in 2018 and is projected to exhibit a CAGR of 4.0% over the forecast period (2019 – 2027).

Increasing R&D in the treatment of immune thrombocytopenic purpura is expected to propel growth of Middle East and Turkey immune thrombocytopenic purpura (ITP) treatment drugs market over the forecast period. For instance, in November 2018, Novartis Pharmaceuticals initiated a clinical trial to assess the efficacy of Eltrombopag in the treatment-free remission in ITP subjects who relapsed or failed to respond to initial steroids treatment.

To know the latest trends and insights related to Middle East and Turkey immune Thrombocytopenic Purpura (ITP) Treatment Drugs Market PRESS RELEASE, click the link below: https://www.coherentmarketinsights.com/press-release/middle-east-and-turkey-immune-thrombocytopenic-purpura-treatment-drugs-market-2572

Government initiatives to enhance healthcare are expected to boost growth of Middle East and Turkey immune thrombocytopenic purpura drugs market. For instance, in 2010, the government of U.A.E launched UAE Vision 2021 to enhance healthcare in the country. Furthermore, in 2015, the UAE government launched a new health insurance scheme in Dubai. Under this scheme 130,000 people get healthcare at 23 private hospitals, and more than 500 medical clinics in and around Dubai. Increasing healthcare expenditure is also expected to aid in growth of the market. For instance, according to the Export Gov. 2019 report, UAE’s healthcare expenditure was US$ 13.7 billion in 2018, and it is expected to reach US$ 18.3 billion by 2023.

Major players in the market are focused on adopting business expansion strategies. For instance, in March 2018, Felix Pharmaceuticals Industries announced the construction of a pharmaceutical plant and logistics center at the Salalah Free Zone in Oman, with an investment of US$ 365 million.

Apply Promo Code “STAYHOME” And Get Instant Discount Of USD 1000
Buy Now This Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/3171

Key Takeaways

• The Middle East and Turkey immune thrombocytopenic purpura (ITP) treatment drugs market is expected to witness a CAGR of 4.0% during the forecast period (2019–2027)
• Among drug type, the steroid segment is expected to account for the largest market share in 2027
• The corticosteroid drug has not received approval in any of the Middle East countries for treatment of ITP
• Major players operating in the Middle East and Turkey Immune Thrombocytopenic Purpura (ITP) Treatment Drugs Market include Amgen Inc., Octapharma AG, Novartis AG, Swedish Orphan Biovitrum AB, and Rigel Pharmaceuticals, Inc.

Have a Look at Related Research Insights:

Antibodies Market, By Product Type (Monoclonal antibodies, Polyclonal antibodies, Antibody-drug complexes (ADCs)), By Disease Indication (CNS Disorders, Cardiovascular Diseases, Cancer, Autoimmune Disorders), By End User (Hospitals, Long-term Care Facilities, Research institutes), and By Region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) – Size, Share, Outlook, and Opportunity Analysis, 2019 – 2027

Pharmaceutical Drug Delivery Market by Route of administration (Oral Drug Delivery, Topical Drug Delivery, Inhalation Drug Delivery, Pulmonary Drug Delivery, Nasal Drug Delivery, Transmucosal Drug Delivery, Injectable Drug Delivery, Ocular Drug Delivery, and Implantable Drug Delivery), By Application (Infectious Diseases, Cancer, Cardiovascular Diseases, Diabetes, Respiratory Diseases, Central Nervous System Disorders, Autoimmune Diseases, and Others), by End Users (Hospitals, Ambulatory Surgical Centers/Clinics, Diagnostic Centers, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Global Industry Insights, Trends, Outlook, and Opportunity Analysis 2019 – 2027

Immune Checkpoint Inhibitors Market by Drug Class (Programmed Death Receptor-1 (PD-1) Inhibitors (Pembrolizumab (Keytruda), Nivolumab (Opdivo), Cemiplimab (Libtayo), Others (Spartalizumab), Programmed Death-Ligand 1 (PD-L1) Inhibitors (Atezolizumab (Tecentriq), Avelumab (Bavencio), Durvalumab (Imfinzi)), Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) Inhibitors (Ipilimumab (Yervoy)), Indoleamine-2,3-dioxygenase (IDO) Inhibitors, Lymphocyte-Activation Gene 3 Inhibitors)), By Cancer Type (Lung Cancer, Head & Neck Cancers, Skin Cancer (Melanoma and Merkel Cell Carcinoma), Blood Cancer (Lymphoma), Bladder Cancer (Urothelial Carcinoma), Renal/Kidney Cancer, Colorectal Cancer, Breast Cancer, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies),  and region (North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa) – Size, Share, Outlook, and Opportunity Analysis, 2018-2026

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website – www.coherentmarketinsights.com

Contact:

Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837

This content has been distributed via CDN Newswire press release distribution service. For press release enquires please mail us at contact@cdnnewswire.com.